Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Testing considerations for novel cell substrates: a regulatory perspective.

Khan AS.

PDA J Pharm Sci Technol. 2010 Sep-Oct;64(5):426-31.

PMID:
21502046
2.

Proposed algorithm to investigate latent and occult viruses in vaccine cell substrates by chemical induction.

Khan AS, Ma W, Ma Y, Kumar A, Williams DK, Muller J, Ma H, Galvin TA.

Biologicals. 2009 Jun;37(3):196-201. doi: 10.1016/j.biologicals.2009.02.016. Epub 2009 Mar 18.

PMID:
19299169
3.

Current testing methods and challenges for detection of adventitious viruses.

Khan AS.

PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):627-33. doi: 10.5731/pdajpst.2011.00831.

PMID:
22294589
4.

Evolution of approaches to viral safety issues for biological products.

Lubiniecki AS.

PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):547-56. doi: 10.5731/pdajpst.2011.00818.

PMID:
22294576
5.

Preclinical development strategies for novel gene therapeutic products.

Pilaro AM, Serabian MA.

Toxicol Pathol. 1999 Jan-Feb;27(1):4-7. Review.

PMID:
10367665
6.

Development of novel influenza virus vaccines and vectors.

Palese P, Zavala F, Muster T, Nussenzweig RS, GarcĂ­a-Sastre A.

J Infect Dis. 1997 Aug;176 Suppl 1:S45-9. Review.

PMID:
9240694
7.

Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine.

Tatalick LM, Gerard CJ, Takeya R, Price DN, Thorne BA, Wyatt LM, Anklesaria P.

Vaccine. 2005 Apr 8;23(20):2628-38.

PMID:
15780446
8.

Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines.

Hess RD, Weber F, Watson K, Schmitt S.

Vaccine. 2012 Apr 5;30(17):2715-27. doi: 10.1016/j.vaccine.2012.02.015. Epub 2012 Feb 17. Review.

PMID:
22342707
10.

Traditional approach preventive HIV vaccines: What are the cell substrate and inactivation issues?

Sheets RL, Goldenthal KL.

AIDS Res Hum Retroviruses. 1998 May 1;14(7):627-33.

PMID:
9591717
11.

Regulatory considerations for raw materials used in biological products.

Khan AS.

PDA J Pharm Sci Technol. 2010 Sep-Oct;64(5):451-7.

PMID:
21502052
12.

Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.

Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, Musiychuk K, Bi H, Farrance C, Shamloul M, Kushnir N, Sharma S, Yusibov V.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:41-50. Epub 2011 Jan 1.

PMID:
21266846
13.
14.

Viruses as vectors.

Bostock CJ.

Vet Microbiol. 1990 Jun;23(1-4):55-71. Review.

PMID:
2119537
15.

Recombinant viruses as vaccines and immunological tools.

Rolph MS, Ramshaw IA.

Curr Opin Immunol. 1997 Aug;9(4):517-24. Review.

PMID:
9287173
16.

Live recombinant vectors for AIDS vaccine development.

Voltan R, Robert-Guroff M.

Curr Mol Med. 2003 May;3(3):273-84. Review.

PMID:
12699363
17.

Detection of adventitious viruses in biologicals--a rare occurrence.

Nims RW.

Dev Biol (Basel). 2006;123:153-64; discussion 183-97.

PMID:
16566443
18.

Detection of Latent Retroviruses in Vaccine-related Cell Substrates: Investigation of RT Activity Produced by Chemical Induction of Vero Cells.

Ma H, Khan AS.

PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):685-9. doi: 10.5731/pdajpst.2011.00843.

PMID:
22294598
19.

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

Rimmelzwaan GF, Sutter G.

Expert Rev Vaccines. 2009 Apr;8(4):447-54. doi: 10.1586/erv.09.4. Review.

PMID:
19348560
20.

New technologies and challenges of novel virus detection.

Khan AS, Ma H, Taliaferro LP, Galvin TA, Shaheduzzaman S.

PDA J Pharm Sci Technol. 2014 Nov-Dec;68(6):661-6. doi: 10.5731/pdajpst.2014.01029.

PMID:
25475641

Supplemental Content

Support Center